16 CFR 1700 - POISON PREVENTION PACKAGING | Title 16 - Commercial Practices | Code of Federal Regulations

prev | next

Authority: 15 U.S.C. 1471-76. Secs. 1700.1 and 1700.14 also issued under 15 U.S.C. 2079(a).

Source: 38 FR 21247, Aug. 7, 1973, unless otherwise noted.

Title 16 published on 2012-01-01

The following are only the Rules published in the Federal Register after the published date of Title 16.

For a complete list of all Rules, Proposed Rules, and Notices view the Rulemaking tab.

2012-12-10; vol. 77 # 237 - Monday, December 10, 2012

77 FR 73294 - Requirements for Child-Resistant Packaging: Products Containing Imidazolines Equivalent to 0.08 Milligrams or More

GPO FDSys XML | Text

Additional Documents

type	regulations.gov
FR Doc.	2012-29203
RIN
CPSC Docket No.	CPSC-2012-0005

CONSUMER PRODUCT SAFETY COMMISSION

Final rule.

Effective date: This rule is effective December 10, 2013. Applicability: This rule applies to products packaged on or after that date.

16 CFR Part 1700

Summary

The Consumer Product Safety Commission (CPSC, Commission, or we) is issuing a rule to require child-resistant (CR) packaging for any over-the-counter or prescription product containing the equivalent of 0.08 milligrams or more of an imidazoline, a class of drugs that includes tetrahydrozoline, naphazoline, oxymetazoline, and xylometazoline, in a single package. Imidazolines are a family of drugs that are vasoconstrictors indicated for nasal congestion and/or ophthalmic irritation. Products containing imidazolines can cause serious adverse reactions, such as central nervous system (CNS) depression, decreased heart rate, and depressed ventilation in children who accidentally ingest them. Based on the scientific data, the Commission has determined that availability of 0.08 milligrams or more of an imidazoline in a single package, by reason of its packaging, is such that special packaging is required to protect children under 5 years old from serious personal injury or illness due to handling or ingesting such a substance. The Commission takes this action under the Poison Prevention Packaging Act of 1970 (PPPA) and voted to publish this notice in the Federal Register .

This is a list of United States Code sections, Statutes at Large, Public Laws, and Presidential Documents, which provide rulemaking authority for this CFR Part.

This list is taken from the Parallel Table of Authorities and Rules provided by GPO [Government Printing Office].

It is not guaranteed to be accurate or up-to-date, though we do refresh the database weekly. More limitations on accuracy are described at the GPO site.

United States Code

USC : Title 15 - COMMERCE AND TRADE

§ 1471 - Definitions

§ 1472 - Special packaging standards

§ 1473 - Conventional packages, marketing

§ 1474 - Regulations for special packaging standards

§ 1475 - Repealed.

§ 1476 - Preemption of Federal standards

Title 16 published on 2012-01-01

The following are ALL rules, proposed rules, and notices (chronologically) published in the Federal Register relating to 16 CFR 1700 after this date.

2012-12-10; vol. 77 # 237 - Monday, December 10, 2012

77 FR 73294 - Requirements for Child-Resistant Packaging: Products Containing Imidazolines Equivalent to 0.08 Milligrams or More

GPO FDSys XML | Text

Additional Documents

type	regulations.gov
FR Doc.	2012-29203
RIN
CPSC Docket No.	CPSC-2012-0005

CONSUMER PRODUCT SAFETY COMMISSION

Final rule.

Effective date: This rule is effective December 10, 2013. Applicability: This rule applies to products packaged on or after that date.

16 CFR Part 1700

Summary

The Consumer Product Safety Commission (CPSC, Commission, or we) is issuing a rule to require child-resistant (CR) packaging for any over-the-counter or prescription product containing the equivalent of 0.08 milligrams or more of an imidazoline, a class of drugs that includes tetrahydrozoline, naphazoline, oxymetazoline, and xylometazoline, in a single package. Imidazolines are a family of drugs that are vasoconstrictors indicated for nasal congestion and/or ophthalmic irritation. Products containing imidazolines can cause serious adverse reactions, such as central nervous system (CNS) depression, decreased heart rate, and depressed ventilation in children who accidentally ingest them. Based on the scientific data, the Commission has determined that availability of 0.08 milligrams or more of an imidazoline in a single package, by reason of its packaging, is such that special packaging is required to protect children under 5 years old from serious personal injury or illness due to handling or ingesting such a substance. The Commission takes this action under the Poison Prevention Packaging Act of 1970 (PPPA) and voted to publish this notice in the Federal Register .

2012-01-25; vol. 77 # 16 - Wednesday, January 25, 2012

77 FR 3646 - Products Containing Imidazolines Equivalent to 0.08 Milligrams or More

GPO FDSys XML | Text

Additional Documents

type	regulations.gov
FR Doc.	2012-1446
RIN
CPSC Docket No.	CPSC-2012-0005

CONSUMER PRODUCT SAFETY COMMISSION

Notice of proposed rulemaking.

Written comments must be received by April 9, 2012.

16 CFR Part 1700

Summary

The Consumer Product Safety Commission (“CPSC,” “Commission,” or “we”) is proposing a rule to require child-resistant (“CR”) packaging for any over-the-counter or prescription product containing the equivalent of 0.08 milligrams or more of an imidazoline, a class of drugs that includes tetrahydrozoline, naphazoline, oxymetazoline, and xylometazoline, in a single package. Imidazolines are a family of drugs that are vasoconstrictors indicated for nasal congestion and/or ophthalmic irritation. Products containing imidazolines can cause serious adverse reactions, such as central nervous system (“CNS”) depression, decreased heart rate, and depressed ventilation in children treated with these drugs or who accidentally ingest them. Based on the scientific data, the Commission preliminarily finds that availability of 0.08 milligrams or more of an imidazoline in a single package, by reason of its packaging, is such that special packaging is required to protect children under 5 years old from serious personal injury or illness due to handling, using, or ingesting such a substance. We are taking this action under the Poison Prevention Packaging Act of 1970 (“PPPA”). 1 1 The Commission voted 4-0 to publish this notice in the Federal Register . Commissioner Robert S. Adler issued a statement, which can be found at http://www.cpsc.gov/pr/statements.html.

16 CFR 1700 - POISON PREVENTION PACKAGING

CFR Toolbox

Law about... Articles from Wex

Find a Lawyer

Get Involved